CAS 2007975-22-4
:Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.
3-Methyl-7-(tetrahydro-2H-pyran-4-yl)-2-((trans-4-(trifluoromethyl)cyclohexyl)methoxy)imidazo[5,1-f][1,2,4]triazin-4(3H)-one
CAS:Formula:C19H25F3N4O3Purity:98%Molecular weight:414.4223-Methyl-7-(Tetrahydro-2H-Pyran-4-Yl)-2-((Trans-4-(Trifluoromethyl)Cyclohexyl)Methoxy)Imidazo[5,1-F][1,2,4]Triazin-4(3H)-One
CAS:<p>3-Methyl-7-(Tetrahydro-2H-Pyran-4-Yl)-2-((Trans-4-(Trifluoromethyl)Cyclohexyl)Methoxy)Imidazo[5,1-F][1,2,4]Triazin-4(3H)-One</p>Purity:98%Molecular weight:414.42g/molDSR-141562
CAS:<p>DSR-141562 is a potent and selective inhibitor of phosphodiesterases. The compound was shown to inhibit the activity of PDE4 selectively, with little or no inhibition of other phosphodiesterases. DSR-141562 has been shown to be effective in animal models for depression and hyperactivity. The drug also has a profile that suggests it may have therapeutic potential for the treatment of neurodevelopmental disorders, including autism spectrum disorder. This drug has been shown to be orally active in animal models and is expressed in tissues such as brain, liver, kidney, heart, lung, and spleen. DSR-141562 inhibits the activity of dopamine transporter (DAT) and norepinephrine transporter (NET), which are proteins that are responsible for removing dopamine from synapses in the brain.</p>Formula:C19H25F3N4O3Purity:Min. 95%Molecular weight:414.4 g/molDSR-141562
CAS:<p>DSR-141562 is a new compound that can be taken orally and has a specific ability to inhibit phosphodiesterase 1 (PDE1) in the brain. This compound exhibits a preference for inhibiting human PDE1B, with an IC50 value of 43.9 nM. It also shows moderate inhibition of human PDE1A (IC50 = 97.6 nM) and PDE1C (IC50 = 431.8 nM). DSR-141562 is particularly useful in the study of positive symptoms, negative symptoms, and cognitive impairments associated with schizophrenia.</p>Formula:C19H25F3N4O3Color and Shape:SolidMolecular weight:414.42
